Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-TECHNE Corp Director's Dealing 2018

Feb 15, 2018

30718_dirs_2018-02-15_9d9005a1-bf00-415f-8670-2418bcdd94cc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2018-02-13

Reporting Person: Dinarello Charles A (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-02-13 Common Stock M 5000 $65.47 Acquired 13212 Direct
2018-02-13 Common Stock S 2495 $135.76 Disposed 10717 Direct
2018-02-13 Common Stock S 2505 $136.36 Disposed 8212 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-02-13 Stock Option (right to buy) $65.47 M 5000 Disposed 2018-10-22 Common Stock (5000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $125.05 2027-10-26 Common Stock (3125) 3125 Direct
Stock Option (right to buy) $101.19 2026-10-26 Common Stock (3985) 3985 Direct
Stock Option (right to buy) $87.34 2025-10-28 Common Stock (4260) 4260 Direct
Stock Option (right to buy) $91.78 2024-10-30 Common Stock (4000) 4000 Direct
Stock Option (right to buy) $87.39 2023-10-30 Common Stock (4000) 4000 Direct
Stock Option (right to buy) $66.90 2022-10-24 Common Stock (5000) 5000 Direct
Stock Option (right to buy) $70.35 2021-10-26 Common Stock (5000) 5000 Direct
Stock Option (right to buy) $61.46 2020-10-27 Common Stock (5000) 5000 Direct
Stock Option (right to buy) $63.03 2019-10-28 Common Stock (5000) 5000 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.61 to $135.875, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.03 to $136.66, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The option vests on the earlier of the one year anniversary of the grant date (10/26/17) or the date of Bio-Techne's 2018 annual meeting of shareholders.